Immunotherapy, which uses the body’s own immune system to fight cancer, is an effective treatment option, yet many patients do not respond to it. Thus, cancer researchers are seeking new ways to optimise immunotherapy so that it is more effective for more people.

Now, Salk Institute scientists have found that manipulating an early step in energy production in mitochondria - the cell’s powerhouses - reduces melanoma tumour growth and enhances the immune response in mice.

The study, published in Science, revealed that when electrons take one of two initial routes through mitochondria, genes and proteins become activated that are needed for immune cells to recognise and kill tumour cells.

“We wanted to better understand how tumours acquire the metabolic state that gives them a growth advantage as well as an ability to evade the immune system, which I call the ‘double whammy,’” says Professor Susan Kaech, the paper’s co-senior author and director of the NOMIS Center for Immunology and Microbial Pathogenesis. “And we found a way to make the tumours more recognisable by the immune system and potentially more responsive to immunotherapy.”

It was previously thought that cancer cells do not rely heavily on mitochondria despite still having oxygen and sugars available to them to fuel mitochondrial metabolism.

This hypothesis dominated the field of cancer metabolism until recently, when scientists found that mitochondria actually play multiple important roles in tumour growth.

“There's an explosion of recent research activity from my lab and others revealing how mitochondria regulate the immune system and inflammation, and this study highlights an exciting new chapter in this story,” says Professor Gerald Shadel, co-senior author, holder of the Audrey Geisel Chair in Biomedical Science, and director of the San Diego Nathan Shock Center of Excellence in the Basic Biology of Aging.

Kaech and Shadel teamed up to better understand how mitochondria influence both tumour growth and the way in which the immune system recognises and responds to cancer.

For this study, their labs altered a key step in the electron transport chain, a process that moves electrons through mitochondria, leading to the production of adenosine phosphate (ATP), the main energy-providing molecule in cells.

There are two primary routes by which electrons flow inside mitochondria to initiate ATP production. When the team forced electrons to primarily go through only one of these two routes, it led to the overproduction of a metabolite called succinate.

This accumulation of succinate led to expression of immune genes in the nucleus and increased the levels of a protein called MHC on the surface of the tumour. In turn, elevated levels of MHC made the tumour cells more visible to specialised immune cells called “killer” T cells, which recognise and eliminate cancer cells.

While the team knew that the metabolic state of tumour cells dictated their enhanced growth properties, this new finding shows that relatively simple manipulations to mitochondrial electron transport can convert a tumour that is evading immune detection into one that is now highly susceptible to immune system attack.

"We were surprised to find that mitochondrial activity determines how susceptible a tumour is to being recognised by the immune system,” says co-first author Kailash Chandra Mangalhara, a senior research associate in Shadel’s lab.

The researchers plan to explore ways to leverage this mechanism to fight cancer without harming mitochondria, which can have adverse effects on normal cells. They will continue to study the role of mitochondrial metabolism in cancer, immune responses, and immunotherapy efficacy.

“We think we found a novel mechanism by which antigen presentation in tumour cells is regulated,” says co-first author Karthik Varanasi, a postdoctoral research associate in Kaech’s lab. “These findings change how we now think about future treatment strategies.”

Source: Salk Institute